Navigation Links
Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
Date:6/16/2008

r the quarter ended March 31, 2008 and other filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
2. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
3. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
4. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
5. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
9. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
10. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
11. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/14/2008)...all/ -- Neuralstem Inc.,(Amex: CUR ) today annou...ntions from Cleveland Clinic pertaining to Targete...entions were developed by Dr. Nicholas,Boulis MD, ...ity., (Logo: http://www.newscom.com/cgi-bin/prnh... have licensed-in these important delivery,technol...
(Date:10/14/2008)...armaceuticals, Inc. today,announced the Company,s ...irst-in-class aminomethylcycline, will be the subj...8th Interscience Conference on Antimicrobial,Agent...Washington, D.C.,from October 25 - October 28, 200...AC:, Sunday, October 26, 12:15 - 1:15 pm EST ...
(Date:10/14/2008)...ing 12-Month Outcomes from, Single- Center Study I...ns, WASHINGTON, Oct. 14 /- OrbusNeic...onth follow-up data from the global e-HEALING,regi...ld use of the,company,s Genous Bio-engineered R st....D., Ph.D., of the Academic,Medical Center in Amst...
(Date:10/13/2008)...g advances study Study needed because of low... 13 /- Advanced Circulatory Systems, ...ced today that it has received,an additional $1.5 ...,Health (NIH) to continue a study testing two devi...rdiac arrest outside a hospital. Whatcom County, W...
Breaking Medicine Technology:Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology 2Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology 3Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 2Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 3Whatcom County, Washington Participating in NIH Study of Cardiac Arrest Resuscitation Techniques 2Volcano Corporation Selects Xactly to Drive Strategic Sales Performance Management 11031 1Volcano Corporation Selects Xactly to Drive Strategic Sales Performance Management 11031 2Volcano Corporation Selects Xactly to Drive Strategic Sales Performance Management 11031 3Ingenious Med Reports Record Sales and Client Expansions in 2007 11028 1Ingenious Med Reports Record Sales and Client Expansions in 2007 11028 2Consumer Reports Poll 3A Americans Demand Health Reform But Are Unsure About How to Achieve it 11025 1Consumer Reports Poll 3A Americans Demand Health Reform But Are Unsure About How to Achieve it 11025 2Consumer Reports Poll 3A Americans Demand Health Reform But Are Unsure About How to Achieve it 11025 3Consumer Reports Poll 3A Americans Demand Health Reform But Are Unsure About How to Achieve it 11025 4Halogen Receives High Ratings from Bersin 26 Associates Company recognized as a market leader and receives praise for outstanding customer satisfa 3031 1Halogen Receives High Ratings from Bersin 26 Associates Company recognized as a market leader and receives praise for outstanding customer satisfa 3031 2
...in-human results for,IMC-A12, a monoclonal antibod...Q: IMCL) and targeted to IGF-1R (insulin-like,grow...annual,meeting of the American Society of Clinical...he cell surface of must human cancers,and transmit...feration, and inhibition of programmed cell death....
...- Elixir,Pharmaceuticals, Inc., announced today ne...s a potential method for regulating,metabolism, de...he,data were presented in poster sessions during E...g, being held in Toronto,Canada. Elixir is focuse... metabolic disease, as well as prevent age-related...
Other Medicine Technology:Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal,Antibody IMC-A12 Presented at ASCO 2Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal,Antibody IMC-A12 Presented at ASCO 3Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 2Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 3Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 4
(Date:10/14/2008)... Also debuts TMR,09 campaign, IRVINE, Calif., O...poration (Pink Sheets: CGCP), a global leader of i...nd the market leader of surgical products for,tran...educational symposium,yesterday in conjunction wit...rapeutics (TCT) meeting in Washington, D.C., The ...
(Date:10/14/2008)... more than 500 accounts Company opening new PROMUS...ICK, Mass., Oct. 14 /PRNewswire-FirstCall/ -- Bost...unced estimated U.S. market shares for,September f...liminary data,from Millennium Research Group (MRG)...he healthcare sector., Based on the MRG data, the...
(Date:10/14/2008)... Leading Supplemental Insurance Company Encour... Employee Benefits , Chic...e , a leading provider of supplemental insurance, ...time to review employee benefits and recommends ,V...to help retain employees. These programs can be a ...
(Date:10/14/2008)...ctober 14 /PRNewswire/ -- Researchers at the Insti... started work on a 3.5 year,project to develop a n...hemical vapour deposition) diamond manufactured by...he field of CVD diamond synthesis and its,applicat...uld open up a raft of new,application areas in, fo...
Breaking Medicine News(10 mins):Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 2Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 3Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 4Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 2Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 3Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 4Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 2Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 3Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 4Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 5Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 2Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 3Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 4
...t patients who develop Parkinson's disease in yout...cohol// abuse may be more likely to develop pathol...ed to treat their condition. Behaviors associated...sive shopping, hypersexuality, binge eating and pa...
... sclerosis (MS) for 10 years and have few of the d...ey// have “benign MS” and that their symptoms will... people with MS. A new study shows that unfortunat...0 years, the disease had progressed in nearly half...
...ge for colorectal cancer screening has increased, ...ng// practices. According to a report published re..., sex, age, education and income levels. Colorec...ncer affecting men and women in the United States ...
... a powerful two-gene test that can distinguish bet... cancers that require radically different courses ... in the online Early Edition of the Proceedings of...iences. "This simple and accurate test has the po...
Other Medicine News:Health News:Compulsive Gambling Linked to Parkinson's Disease Medications 2Health News:Disparities in Colon Cancer Screening Remain Among Medicare Patients 2Health News:A New Two-gene Test to Discern Similar Gastrointestinal Cancers 2
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
Medicine Products: